Article
Boehringer Acquires Rights to Potential CF Inhalation Gene Therapy
Rating:
0.0
Views:
77
Likes:
1
Library:
1
Boehringer Ingelheim has taken legal steps giving it the lead role in further development of a long-lasting, inhalation gene therapy for cystic fibrosis (CF), called BI 3720931, that stems from a public-private research effort begun in 2018. The 2018 agreement brought together Boehringer, the...
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value